Performance & GH axis
CJC-1295
Growth Hormone Releasing Hormone Analog
A modified version of a natural hormone that tells your pituitary gland to release more growth hormone. Often combined with Ipamorelin for enhanced effects.
Also known as: Mod GRF 1-29, CJC1295
- Status
- CJC-1295 is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- ~6-8 days (with DAC)
- How it's taken
- Subcutaneous injection
- Mechanism
- Growth-hormone secretagogue
- Pathways
- GHRH analogue, GH axis
How CJC-1295 works
Binds to growth hormone releasing hormone (GHRH) receptors in the pituitary gland, triggering a sustained release of growth hormone. The 'DAC' version has an extended half-life by binding to albumin in the blood.
What research has looked at
- Increased growth hormone levels
- Improved muscle recovery and growth
- Better sleep quality
- Enhanced fat metabolism
- Increased collagen production
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Water retention
- Tingling or numbness in hands/feet
- Increased hunger
- Headache
- Flushing or warmth after injection
- Joint pain at higher doses
Sources
- PubMed research on CJC-1295 GHRH analog · NIH · National Library of Medicine
- DrugBank record for CJC-1295 · DrugBank
- Active clinical trials for CJC-1295 · U.S. National Library of Medicine
Track CJC-1295 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
CJC-1295 FAQ
What is CJC-1295?
A modified version of a natural hormone that tells your pituitary gland to release more growth hormone. Often combined with Ipamorelin for enhanced effects.
How does CJC-1295 work?
Binds to growth hormone releasing hormone (GHRH) receptors in the pituitary gland, triggering a sustained release of growth hormone. The 'DAC' version has an extended half-life by binding to albumin in the blood.
Is CJC-1295 FDA approved?
No. CJC-1295 is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of CJC-1295?
Reported half-life: ~6-8 days (with DAC).
How is CJC-1295 taken?
Subcutaneous injection.
What side effects have been reported with CJC-1295?
Reported in the sources: Water retention; Tingling or numbness in hands/feet; Increased hunger; Headache; Flushing or warmth after injection; Joint pain at higher doses.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.